Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AZD6244: Phase II data

In an open-label, international Phase II trial in 88 patients,

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE